STOCKHOLM, Oct. 5, 2026 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB) today announcedthe publication of new analyses demonstrating potent antifungal activity of terbinafine against dermatophytes causing onychomycosis. Importantly, mycological cure with MOB-015 was achieved across the full...
Una nueva investigación europea revela que el 81 % reconoce la importancia de proteger la piel más allá de los rayos UV; sin embargo, solo el 22 % utiliza productos destinados a reforzar la barrera cutánea. VIENA, 5 de octubre de 2026 /PRNewswire/ -- CeraVe, la marca de cuidado de la piel...
Published multicenter study found higher complete wound closure rates and faster healing with Symphony plus standard of care AUCKLAND, New Zealand, Oct. 5, 2026 /PRNewswire/ -- Aroa Biosurgery Limited (ASX: ARX), a soft tissue regeneration company, today announced positive results from a...
The only known investigational therapy for SBMA in Phase 3 development worldwide AJ201 (rosolutamide) is an investigational oral small molecule designed to address multiple disease mechanisms of spinal and bulbar muscular atrophy (SBMA, or Kennedy's disease) Following submission of the...
MAILAND, 5. Oktober 2026 /PRNewswire/ -- Auf der Tagung der Europäischen Vereinigung für Diabetesforschung (EASD) 2026 präsentierte SiBionics unter dem Motto „See More, Act Earlier" die Verknüpfung von kontinuierlicher Messtechnik mit der Diabetesversorgung der Zukunft. Diese Vision wurde...
HAMILTON, ON, Oct. 4, 2026 /PRNewswire/ -- Latitude Air Ambulance today issued the following statement regarding Heartbeat 104 Medevac, which was operating from Bermuda to Boston, Massachusetts: It is with profound sadness that we acknowledge the decision by the United States Coast Guard...
Shionogi & Co., Ltd. and Teikoku Ventures, Inc. Join the Round to Accelerate U.S. Clinical Trial Preparations for CLD-001 TOKYO, Oct. 4, 2026 /PRNewswire/ -- Celaid Therapeutics Inc. (Head Office: Bunkyo-ku, Tokyo, Japan; President and CEO: Nobuyuki Arakawa; "Celaid") today announced the...
MILAN, 5 octobre 2026 /PRNewswire/ -- Lors du congrès 2026 de l'Association européenne pour l'étude du diabète (EASD), SiBionics a présenté « See More, Act Earlier » (Voir plus : agir plus tôt), qui établit un lien entre la surveillance continue et l'avenir de la prise en charge du...
Alentis to receive US$355 million initial payment and up to US$1.2 billion in commercial milestones, with global profits shared MELBOURNE, Australia and BASEL, Switzerland, Oct. 4, 2026 /PRNewswire/ -- CSL and Alentis Therapeutics today announced they have entered into an exclusive global...
МИЛАН, 5 октября 2026 г. /PRNewswire/ -- На конференции Европейской ассоциации по изучению диабета (EASD) 2026 года компания SiBionics представила программу «Видеть больше, действовать раньше», которая связывает постоянный мониторинг с лечением диабета в будущем. Три главы выставки...